BG Medicine Inc., a Waltham, Mass.-based developer of molecular diagnostics based on biomarkers, has filed for an $80 million IPO. It plans to trade on the Euronext Amsterdam under ticker symbol BGMDX, with Cowen International and Fortis serving as co-lead underwriters. BG Medicine has raised around $37 million in VC funding since 2000, from firms like Flagship Ventures (48.8% pre-IPO stake), Gilde Investment Management (14.6%) and Koniklijke Philips Electronics (6.5%).
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.